Merck & Eisai的癌症药物组合显示,在一些但并非所有主要的肠胃癌试验中都取得了进展。 Merck & Eisai's cancer drug combo shows progress in some but not all key trials for gastroesophageal cancer.

Merck & Co.和Eisai的Keytruda和Lenvima关于胃镜癌的第三阶段研究显示,在统计上,在无进展生存方面有了显著改善,但没有达到总体生存的主要终点。 Merck & Co. and Eisai's Phase 3 study of Keytruda and Lenvima in gastroesophageal cancer showed a statistically significant improvement in progression-free survival but did not meet the primary endpoint of overall survival. 综合治疗的安全情况与先前的研究一致。 The combination treatment's safety profile was consistent with previous studies. 这些药物被批准用于几种癌症,并正在研究其他癌症。 The drugs are approved for several cancers and are under study for others.